EP0000764B1 - Anticonceptive agent containing a peptide - Google Patents
Anticonceptive agent containing a peptide Download PDFInfo
- Publication number
- EP0000764B1 EP0000764B1 EP78100564A EP78100564A EP0000764B1 EP 0000764 B1 EP0000764 B1 EP 0000764B1 EP 78100564 A EP78100564 A EP 78100564A EP 78100564 A EP78100564 A EP 78100564A EP 0000764 B1 EP0000764 B1 EP 0000764B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide
- compound
- anticonceptive
- mcg
- agent containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 5
- 239000003433 contraceptive agent Substances 0.000 title claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 description 12
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- DDCPKNYKNWXULB-RXMQYKEDSA-N (2r)-2-azaniumyl-3-[(2-methylpropan-2-yl)oxy]propanoate Chemical compound CC(C)(C)OC[C@@H]([NH3+])C([O-])=O DDCPKNYKNWXULB-RXMQYKEDSA-N 0.000 description 1
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/13—Luteinizing hormone-releasing hormone; related peptides
Definitions
- the invention relates to an anti-conception agent based on a peptide of the general formula in which X stands for D-serine tert-butyl ether.
- the compound of formula I is prepared according to DOS 2 438 350. After a single dose in doses of 1.4-20 mcg (this corresponds to 20-300 ng / kg) intravenously (iv) 50-1000 mcg (this corresponds to 100-5000 ng / kg) intranasally (in) in test subjects the release of gonadotropins from the anterior pituitary lobe.
- the dosage is z. B. 3 x 5 mcg daily. c., i. v. or I. m., but can be safely increased to a multiple, since the peptide is non-toxic. In practice one moves between 5-500 mcg daily. With intranasal use, this dose has to be increased by about 100 times because of the absorption of only approx. 1%.
- the agent according to the invention can be used in men to temporarily suppress testosterone production and thus spermatogenesis, and in women to suppress ovulation.
- the application for women begins. e.g. B. on the first day of the cycle and is continued for at least 14 days. In this way, ovulation is definitely prevented during the treatment period.
- the LH level drops to basal values and stimulation of the pituitary gland is no longer possible. With short-term treatment, it is suppressed. The latter may also apply to the nidation, since both processes depend on the level of the FSH and LH levels.
- the z. B. with steroid-containing contraceptives to be considered residue and metabolism problems.
- the preparations according to the invention contain peptides that are easily broken down into amino acids in the body and excreted or metabolized via these amino acids in a physiological manner.
- Compound of formula can be used e.g. B. in physiological saline intravenously, intramuscularly or subcutaneously.
- aqueous or oily preparations for intranasal application are particularly suitable for long-term treatment.
- rectal or vaginal use is also possible.
- Testosterone levels were measured by radioimmunoassay. There was a reduction in the plasma testosterone level to approximately Y, the initial value. Testosterone levels were measured again 6 weeks after stopping treatment. They were back to normal.
- Ovulation was postponed with short-term treatment, but was completely suppressed with longer treatment.
- testicular atropy occurred in the course of treatment, but testicular size increased significantly 8 weeks after treatment was discontinued and the animals showed normal sex drive.
- 500 mg of compound I are dissolved in 100 liters of physiological saline. It is filtered sterile and filled into ampoules of 1 ml each. This preparation can be used for intravenous, intramuscular or subcutaneous administration of the compound I.
- 600 mg of compound I are dissolved in 100 I of isotonic aqueous mannitol solution and treated as in Example 1.
- the ampouled solution is freeze-dried for use again in 1 ml of dist. Water dissolved.
- 1 ml of solution is e.g. B. filled into a container that is provided with a dispensing metering valve that releases 0.05 ml of the solution per application.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Reproductive Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Gegenstand der Erfindung ist ein Antikonzeptionsmittel auf der Grundlage eines Peptids der allgemeinen Formel
Die Verbindung der Formel I wird gemäss DOS 2 438 350 hergestellt. Sie bewirkt nach einmaliger Gabe in Dosierungen von 1.4-20 mcg (das entspricht 20-300 ng/kg) intravenös (i. v.) 50-1000 mcg (das entspricht 100-5000 ng/kg) intranasal (i. n.) bei Versuchspersonen die Ausschüttung von Gonadotropinen aus den Hypophysen-Vorderlappen.The compound of formula I is prepared according to DOS 2 438 350. After a single dose in doses of 1.4-20 mcg (this corresponds to 20-300 ng / kg) intravenously (iv) 50-1000 mcg (this corresponds to 100-5000 ng / kg) intranasally (in) in test subjects the release of gonadotropins from the anterior pituitary lobe.
Es wurde nun gefunden, dass bei wiederholter täglicher Dosierung über mindestens 4 Tage von mehr als 2,5 mcg i. v., s. c. oder i. m. (Tagesdosis) bzw. mehr als etwa 100 mcg i. n. die Wirkung sich nicht verstärkt, sondern überraschenderweise umkehrt, so dass bei entsprechender Dosierung diese Verbindung als Antikonzeptivum verwendet werden kann.It has now been found that with repeated daily dosing of at least 4 days of more than 2.5 mcg i. v., s. c. or I. m. (Daily dose) or more than about 100 mcg i. n. the effect does not increase, but surprisingly reverses, so that this compound can be used as an anti-conceptional agent with the appropriate dosage.
Die Dosierung beträgt z. B. täglich 3 x 5 mcg s. c., i. v. oder i. m., kann aber unbedenklich auf das Vielfache gesteigert werden, da das Peptid untoxisch ist. In praxi bewegt man sich zwischen 5-500 mcg täglich. Bei intranasaler Anwendung muss diese Dosis wegen der Resorption von nur ca. 1% auf das etwa Hundertfache angehoben werden.The dosage is z. B. 3 x 5 mcg daily. c., i. v. or I. m., but can be safely increased to a multiple, since the peptide is non-toxic. In practice one moves between 5-500 mcg daily. With intranasal use, this dose has to be increased by about 100 times because of the absorption of only approx. 1%.
Das erfindungsgemässe Mittel kann beim Mann zur temporären Unterdrückung der Testosteronproduktion und damit Spermatogenese verwendet werden, bei der Frau zur Unterdrückung der Ovulation. Die Applikation bei der Frau beginnt . z. B. am ersten Zyklustag und wird jeweils mindestens 14 Tage fortgesetzt. Auf diese Weise wird die Ovulation während des Behandlungszeitraumes mit Sicherheit verhindert. Der LH-Spiegel sinkt auf Basalwerte, und eine Stimulierung der Hypophyse ist nicht mehr möglich. Bei kurzzeitiger Behandlung wird sie unterdrückt. Letzteres gilt ggf. auch für die Nidation, da beide Vorgänge von der Höhe des FSH- und LH-Spiegels abhängen.The agent according to the invention can be used in men to temporarily suppress testosterone production and thus spermatogenesis, and in women to suppress ovulation. The application for women begins. e.g. B. on the first day of the cycle and is continued for at least 14 days. In this way, ovulation is definitely prevented during the treatment period. The LH level drops to basal values and stimulation of the pituitary gland is no longer possible. With short-term treatment, it is suppressed. The latter may also apply to the nidation, since both processes depend on the level of the FSH and LH levels.
Bisher war versucht worden, die LH- und FSH-Ausschüttung durch Anwendung kompetitiver Hemmer des LH-RH zu unterdrücken. Das gelang aber nur unzureichend und mit Konzentrationen, die um das etwa Tausendfache höher liegen als die der erfindungsgemässen Verbindung.So far, attempts have been made to suppress LH and FSH release by using competitive inhibitors of the LH-RH. However, this was insufficient and with concentrations which are about a thousand times higher than that of the compound according to the invention.
Zudem entfallen die z. B. bei steroidhaltigen Kontrazeptiva zu berücksichtigenden Rückstands-und Metabolismusprobleme. Die erfindungsgemässen Zubereitungen enthalten Peptide, die im Körper leicht zu Aminosäuren abgebaut und ausgeschieden oder über diese Aminosäuren in physiologischer Weise metabolisiert werden.In addition, the z. B. with steroid-containing contraceptives to be considered residue and metabolism problems. The preparations according to the invention contain peptides that are easily broken down into amino acids in the body and excreted or metabolized via these amino acids in a physiological manner.
Verbindung der Formel kann zur Verwendung z. B. in physiologischer Kochsalzlösung intravenös, intramuskulär oder subkutan appliziert werden. Als medizinisch besonders wertvolle Anwendungsform eignen sich insbesondere für Dauerbehandlung wässrige oder ölige Zubereitungen zur intranasalen Applikation. In Form einer Zubereitung als Zäpfchen ist auch rektale oder vaginale Anwendung möglich.Compound of formula can be used e.g. B. in physiological saline intravenously, intramuscularly or subcutaneously. As a medically particularly valuable form of application, aqueous or oily preparations for intranasal application are particularly suitable for long-term treatment. In the form of a suppository preparation, rectal or vaginal use is also possible.
3 Männer im Alter von 30 - 55 Jahren erhielten 10 Tage lang täglich 50 mcg Verbindung 1 subkutan in wässriger Zubereitung. Die Testosteronspiegel wurden durch Radioimmunoassay gemessen. Es fand sich eine Senkung der Testosteronspiegel im Plasma auf ca. Y, des Ausgangswertes. 6 Wochen nach Absetzen der Behandlung wurden die Testosteronspiegel erneut gemessen. Sie hatten wieder ihren normalen Wert erreicht.3 men aged 30-55 years received 50 mcg of compound 1 subcutaneously in aqueous preparation for 10 days. Testosterone levels were measured by radioimmunoassay. There was a reduction in the plasma testosterone level to approximately Y, the initial value. Testosterone levels were measured again 6 weeks after stopping treatment. They were back to normal.
Dieselben Ergebnisse wurden erhalten, wenn 10 Tage lang täglich 2 mg in öliger Zubereitung intranasal verabreicht wurden.The same results were obtained when 2 mg daily in oily preparation was administered intranasally for 10 days.
4 Frauen im Alter von 22 - 30 Jahren erhielten täglich 3 x 5 mcg Verbindung I subkutan in wässriger Zubereitung ab Zyklusbeginn. Wenige Tage nach Behandlung waren die Plasmaspiegel an luteinisierenden und follikelstimulierendem Hormon auf Basalwerte abgesunken und eine Stimulierung der Hypophyse trat nicht mehr ein.4 women aged 22-30 years received 3 x 5 mcg compound I subcutaneously in aqueous preparation from the start of the cycle. A few days after treatment, the plasma levels of luteinizing and follicle-stimulating hormone had dropped to basal levels and the pituitary no longer stimulated.
Bei kurzzeitiger Behandlung wurde die Ovlation verschoben, während sie bei längerer Behandlung ganz unterdrückt wurde.Ovulation was postponed with short-term treatment, but was completely suppressed with longer treatment.
2 Gruppen von je 5 geschlechtsreifen, reinrassigen Beagle-Rüden, Gewicht 6-8 kg, erhielten 1 x täglich 2.5 mcg/kg Verbindung I in isotonischer Kochsalzlösung subkutan verabreicht. Die Testosteronspiegel sanken bereits nach 1 Monat auf 30% des Ausgangswerts, nach 3 Monaten auf 6% des Ausgangswertes ab.2 groups of 5 sexually mature, pure-bred beagle males, weight 6-8 kg, received 1 x daily 2.5 mcg / kg compound I in isotonic saline solution subcutaneously. Testosterone levels dropped to 30% of baseline after 1 month and to 6% of baseline after 3 months.
Die Behandlung wurde 6 Monate fortgesetzt. Im Verlauf der Behandlung trat deutliche Hodenatropie auf, jedoch stieg 8 Wochen nach Absetzen der Behandlung die Hodengrösse wieder deutlich an, und die Tiere zeigten einen normalen Geschlechtstrieb.The treatment was continued for 6 months. Significant testicular atropy occurred in the course of treatment, but testicular size increased significantly 8 weeks after treatment was discontinued and the animals showed normal sex drive.
In den folgenden Beispielen wird die Zubereitung entsprechender Präparate beschrieben.The preparation of corresponding preparations is described in the following examples.
500 mg Verbindung I werden in 100 Liter physiologischer Kochsalzlösung gelöst. Man filtriert steril und füllt in Ampullen zu je 1 ml ab. Diese Zubereitung kann zur intravenösen, intramuskulären oder subkutanen Verabreichung der Verbindung I dienen.500 mg of compound I are dissolved in 100 liters of physiological saline. It is filtered sterile and filled into ampoules of 1 ml each. This preparation can be used for intravenous, intramuscular or subcutaneous administration of the compound I.
600 mg Verbindung I werden in 100 I isotonischer wässriger Mannitlösung gelöst und wie in Beipiel 1 weiterbehandelt. Die ampullierte Lösung wird gefriergetrocknet zum Gebrauch wieder in 1 ml dest. Wasser gelöst.600 mg of compound I are dissolved in 100 I of isotonic aqueous mannitol solution and treated as in Example 1. The ampouled solution is freeze-dried for use again in 1 ml of dist. Water dissolved.
9 1 dest. Wasser werden zum Sieden erhitzt und darin 20 g 4-Hydroxybenzoesäure-methylester gelöst. Man kühlt auf ca. 30° C, gibt 89,6 g Na2NP04, 13.5 g Citronensäure, 10 g Natriumchlorid und 250 g Mannit zu und löst dann darin 100 g Verbindung I. Dann füllt man mit dest. Wasser auf 10 I auf und filtriert.9 1 dest. Water is heated to boiling and 20 g of methyl 4-hydroxybenzoate are dissolved in it. The mixture is cooled to about 30 ° C., 89.6 g of Na 2 NP0 4 , 13.5 g of citric acid, 10 g of sodium chloride and 250 g of mannitol are added, and 100 g of compound I are then dissolved therein. Then the mixture is filled with dist. Water to 10 l and filtered.
1 ml Lösung wird z. B. in einen Behälter gefüllt, der mit einem Entnahme-Dosierventil versehen ist, das pro Applikation 0.05 ml der Lösung freigibt.1 ml of solution is e.g. B. filled into a container that is provided with a dispensing metering valve that releases 0.05 ml of the solution per application.
10 g Benzylalkohol werden mit 2-0ctyldodeka- . nol auf 0.990 I aufgefüllt. Dazu gibt man 10 mg mikrofein gemahlene Verbindung I und homogenisiert.10 g of benzyl alcohol are mixed with 2-0ctyldodeca- . nol to 0.990 I. 10 mg of microfine ground compound I are added and homogenized.
1-2 ml dieser Suspension werden in kleine Behälter abgefüllt. Die Behälter sind mit einem Entnahmeventil versehen, das pro Applikation 0.05 ml der Suspension freigibt.1-2 ml of this suspension are filled into small containers. The containers are equipped with a sampling valve that releases 0.05 ml of the suspension per application.
2 kg handelsüblicher Suppositorienmassen wird auf ca. 60° C erwärmt. Man versetzt mit 2 g mikrofein gemahlener Verbindung I und homogenisiert. Die Masse wird in Formen gegossen, die nach dem Erkalten Suppositorien im Gewicht von jeweils 2 g freigeben.2 kg of commercially available suppository masses are heated to approx. 60 ° C. 2 g of microfine ground compound I are added and the mixture is homogenized. The mass is poured into molds that release suppositories weighing 2 g each after cooling.
Claims (1)
- A contraceptive drug containing a peptide of the formula I
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE8181103936T DE2862466D1 (en) | 1977-08-06 | 1978-08-01 | Use of a luteinising peptide as anti-contraceptive |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19772735515 DE2735515A1 (en) | 1977-08-06 | 1977-08-06 | USE OF LH-RH PEPTIDES AS AN ANTICONCEPTIVE |
| DE2735515 | 1977-08-06 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP81103936.1 Division-Into | 1981-05-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0000764A1 EP0000764A1 (en) | 1979-02-21 |
| EP0000764B1 true EP0000764B1 (en) | 1982-05-05 |
Family
ID=6015797
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP78100564A Expired EP0000764B1 (en) | 1977-08-06 | 1978-08-01 | Anticonceptive agent containing a peptide |
| EP81103936A Expired EP0037127B1 (en) | 1977-08-06 | 1978-08-01 | Use of a luteinising peptide as anti-contraceptive |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP81103936A Expired EP0037127B1 (en) | 1977-08-06 | 1978-08-01 | Use of a luteinising peptide as anti-contraceptive |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4263282A (en) |
| EP (2) | EP0000764B1 (en) |
| JP (1) | JPS5428831A (en) |
| DE (3) | DE2735515A1 (en) |
| IT (1) | IT1097629B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4652443A (en) * | 1983-06-07 | 1987-03-24 | Japan Atomic Energy Research Institute | Slow-release composite and process for producing the same |
| DE3414595A1 (en) * | 1984-04-18 | 1985-10-31 | Hoechst Ag, 6230 Frankfurt | USE OF GONADOLIBERIN AND GONADOLIBERINAGONISTS FOR TREATING CLIMATE COMPLAINTS |
| EP0164669B1 (en) * | 1984-06-13 | 1991-01-23 | Röhm Gmbh | Process for coating pharmaceutical forms |
| US4762717A (en) * | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
| JPS6311675A (en) * | 1986-07-03 | 1988-01-19 | Nippon Mining Co Ltd | Electroless plating method for alumina substrate |
| US4975420A (en) * | 1987-09-30 | 1990-12-04 | University Of Saskatchewan | Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals |
| CA2029018A1 (en) * | 1989-11-01 | 1991-05-02 | Robert P. Millar | Analogues of gonadotropin releasing hormone |
| US5433219A (en) * | 1992-09-23 | 1995-07-18 | Spery; Nanette S. | Receptive condom assembly |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS180644B2 (en) * | 1973-09-29 | 1978-01-31 | Takeda Chemical Industries Ltd | Process for preparing nonapeptides |
| US3914412A (en) * | 1973-10-11 | 1975-10-21 | Abbott Lab | {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity |
| DE2438350C3 (en) * | 1974-08-09 | 1979-06-13 | Hoechst Ag, 6000 Frankfurt | Peptides with a strong LH-RH / FSH-RH action, process for their production and pharmaceutical preparations containing them |
| US3928307A (en) * | 1974-11-04 | 1975-12-23 | American Home Prod | P-Glu-D-Phe-Trp-Ser-Tyr-D-Phee-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4010261A (en) * | 1974-11-25 | 1977-03-01 | Abbott Laboratories | Method to prevent reproduction with [Des-Gly]10 -GN-RH nonadeptide amide analogs in position |
| US4010256A (en) * | 1975-07-30 | 1977-03-01 | Professional Staff Association Of The Los Angeles County Harbor General Hospital | Male contraceptive and method of achieving male contraception |
| US4034082A (en) * | 1976-03-01 | 1977-07-05 | Abbott Laboratories | Method to prevent reproduction in warm-blooded female animals with nonapeptides |
| DE2617646C2 (en) * | 1976-04-22 | 1986-07-31 | Hoechst Ag, 6230 Frankfurt | Nonapeptide-amides and decapeptide-amides with gonadoliberin activity, processes for their preparation and pharmaceutical preparations containing these compounds |
-
1977
- 1977-08-06 DE DE19772735515 patent/DE2735515A1/en not_active Withdrawn
-
1978
- 1978-08-01 DE DE7878100564T patent/DE2861783D1/en not_active Expired
- 1978-08-01 DE DE8181103936T patent/DE2862466D1/en not_active Expired
- 1978-08-01 EP EP78100564A patent/EP0000764B1/en not_active Expired
- 1978-08-01 EP EP81103936A patent/EP0037127B1/en not_active Expired
- 1978-08-04 IT IT26535/78A patent/IT1097629B/en active
- 1978-08-05 JP JP9504178A patent/JPS5428831A/en active Granted
-
1979
- 1979-11-20 US US06/096,029 patent/US4263282A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US4263282A (en) | 1981-04-21 |
| EP0037127A1 (en) | 1981-10-07 |
| DE2862466D1 (en) | 1985-06-27 |
| IT7826535A0 (en) | 1978-08-04 |
| EP0000764A1 (en) | 1979-02-21 |
| DE2735515A1 (en) | 1979-02-22 |
| IT1097629B (en) | 1985-08-31 |
| DE2861783D1 (en) | 1982-06-24 |
| EP0037127B1 (en) | 1985-05-22 |
| JPH0130808B2 (en) | 1989-06-22 |
| JPS5428831A (en) | 1979-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3750764T2 (en) | CONTINUOUS ADMINISTRATION OF LUTEINIZING HORMONE DELIVERING HORMONS IN COMBINATION WITH SEXSTEROID ADMINISTRATION AS A CONSTANT PREVENTION AGENT. | |
| DE2856393C2 (en) | Medicines used to treat Parkinson's disease | |
| DE60315964T2 (en) | IMPROVEMENT OF THE MANUFACTURE OF ENDOGENIC GONADOTROPINE | |
| DE69404675T2 (en) | PHARMACEUTICAL COMPOSITION FOR INTRANASAL ADMINISTRATION OF HYDROXOCOBALAMINE | |
| AT394947B (en) | METHOD FOR PRODUCING A LIQUID NASAL ADDIBLE CALCITONINE COMPOSITION | |
| EP0037127B1 (en) | Use of a luteinising peptide as anti-contraceptive | |
| DE69120387T2 (en) | Medicines containing danazol used to treat endometriosis | |
| DE2348334C2 (en) | New form of preparation of N-4- [2- (5-chloro-2-methoxybenzamido) ethyl] -phenyl-sulfonyl-N'-cyclohexylurea | |
| DE69232942T2 (en) | PRODUCTS FOR THE TREATMENT OF GLAUCOMA | |
| DE3317692A1 (en) | USE OF METKEPHAMIDE OR A PHARMACEUTICALLY SAFE SALT THEREOF AS AN ANALGETIC IN SUBSTANTIVE FEMALE ANIMALS AND ESPECIALLY IN PREGNANT WOMEN | |
| DE2208787A1 (en) | Viral remedies | |
| DE69301750T2 (en) | Use of 1-alpha, 24 (R) -dihydroxy-22 (E) -dehydrovitamin-D3 for the manufacture of a medicament for the treatment of osteoporosis | |
| EP0083925B1 (en) | Method of treatment to induce ovulation in sheep or heifers | |
| DE2708125C2 (en) | ||
| DE69328102T2 (en) | USE OF POISON FROM SKIN FLIGHTERS (HYMENOPTERES) FOR PRODUCING A MEDICINE FOR TREATING INFECTIONS BY DNA VIRUSES | |
| DE69827017T2 (en) | COMBINATIONS OF ENDOMETRICALLY PROTECTED AND ENDOMETRICALLY ATROPHOSED AGENTS WITH ESTROGENIC IN ORAL CONCENTRATION PREVENTION | |
| DE69127541T2 (en) | PHARMACEUTICAL COMPOSITION | |
| DE69006032T2 (en) | METHOD FOR TREATING INFERTILITY OR REDUCED FERTILITY IN ADULTS AND THE USE OF PREPARATIONS IN THIS METHOD. | |
| Westman | Untersuchungen über die Wirkung des gonadotropen Hypophysenvorderlappenhormones, Antex (Leo), auf die Ovarien der Frau | |
| EP0158987B1 (en) | Use of gonadoliberin and its antagonists for preparing a medicament for treating menopause disorders | |
| DE2633891C2 (en) | Tris (hydroxymethyl) aminomethane salt of 2- (5-benzoylthienyl) -α-methyl acetic acid, process for its preparation and pharmaceutical compositions containing it | |
| DE3728367C1 (en) | Means for immunizing the human body against HIV infections | |
| DE2538843A1 (en) | WATER-SOLUBLE PHARMACEUTICAL COMPLEX, PROCESS FOR ITS MANUFACTURING AND PHARMACEUTICAL PREPARATIONS WHICH CONTAIN IT | |
| Groh et al. | ORALE DAUERTHERAPIE MIT CLONAZEPAM (Ro 5‐4023) BEI EPILEPSIEN DES KINDES‐UND JUGENDALTERS | |
| WO2001070203A2 (en) | Agent for treating hepatitis c containing ukrain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Designated state(s): BE CH DE FR GB NL |
|
| 17P | Request for examination filed | ||
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Designated state(s): BE CH DE FR GB NL |
|
| REF | Corresponds to: |
Ref document number: 2861783 Country of ref document: DE Date of ref document: 19820624 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19940718 Year of fee payment: 17 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19940720 Year of fee payment: 17 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19940721 Year of fee payment: 17 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19940809 Year of fee payment: 17 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19940831 Year of fee payment: 17 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19941014 Year of fee payment: 17 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19950801 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19950831 Ref country code: BE Effective date: 19950831 |
|
| BERE | Be: lapsed |
Owner name: HOECHST A.G. Effective date: 19950831 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19960301 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19950801 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19960430 |
|
| NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19960301 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19960501 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |